Voluntary nationwide recall: Cyclobenzaprine (Unichem – August 2025)

Sep. 2025Pharmacy Updates

Unichem Pharmaceuticals (USA), Inc. is recalling one lot, lot GMML24026A, of Cyclobenzaprine Hydrochloride Tablets USP 10 mg. Cyclobenzaprine is used for the relief of muscle spasms from certain conditions.

This drug is being recalled because a Cyclobenzaprine 10 mg (90-count) label was accidentally placed on a bottle containing Meloxicam 7.5 mg tablets. Meloxicam is a nonsteroidal anti-inflammatory drug and is used for the treatment of certain types of arthritis. Meloxicam Tablets, USP, 7.5 mg are light yellow, round, flat, beveled-edged tablets with “U & L” debossed on one side and “7.5” debossed on the other side. Using Meloxicam unknowingly if it is not prescribed for you may cause any of several different serious adverse events—particularly in people taking other nonsteroidal anti-inflammatory drugs or blood thinners, people who have allergies to Meloxicam, or people with underlying illness.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Cyclobenzaprine, you should stop using the product and return it to the place of purchase. If you have experienced any problems that may be related to taking this product, you should contact your doctor or health care provider.

As of Aug. 27, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Inmar at 1-877-840-5109. TTY users should call 711. Help is available Monday through Friday from 9 a.m. to 5 p.m. CST.
  • Visit the FDA website.

Recent Announcements

Community Care Behavioral Health is excited to announce this free upcoming web-based training opportunity:

A growing body of U.S. and international research demonstrates that the rapid legalization and commercialization of gambling—including online casinos and mobile sports betting platforms—are associated with significant and escalating gambling related harm. Although Pennsylvania specific prevalence data remain limited, available evidence is increasingly concerning, with gambling disorder linked to alarmingly high rates of suicide, psychiatric comorbidity, and social and financial harm. Drawing on lessons from the tobacco and opioid crises, this presentation will examine how delayed recognition and regulation can amplify population level harm, underscoring the need for earlier screening, prevention, and policy engagement. Participants will gain practical guidance on identifying patients at elevated risk, implementing evidence informed screening and diagnostic strategies, and applying current treatment approaches across the lifespan.
May 2026Education/Webinars

Bridging Smiles and Systems: Collaborative Care for Children with Chronic Conditions

Please join us for a live, CME-accredited and CEU-accredited webinar on May 13 from noon to 1p.m., that will explore the critical connection between oral health and pediatric chronic conditions such as diabetes, asthma, congenital heart disease, and ADHD.
Apr. 2026Education/Webinars

Certified Community Health Worker (CCHW) Provider Billing Notification

UPMC for You will now reimburse for up to three certified community health worker (CCHW) visits per member per calendar year for Medicaid recipients, per the Pennsylvania Department of Human Services (PA DHS).
Apr. 2026Important Notices